Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orchestra Therapeutics Inc.

Division of Immune Response BioPharma Inc.
www.imnr.com

Latest From Orchestra Therapeutics Inc.

Can Big Pharma Save Biotech Investors?

All the biotech stock indices are down; record numbers of companies are selling at lower-than-cash valuations. Investors want Pharma to step up and buy, removing inventory from the market, and spreading limited investment dollars over a smaller set of opportunities. While buyers say they aren't going to radically change their strategies simply to take advantage of cheap prices, it's clear that more deals will get signed - mostly because more sellers will accept terms they once would have rejected. . In short, a hotter dealmaking climate will keep biotech healthy enough to survive as an industry, albeit a smaller one, and, perhaps, with a slightly lower ceiling on returns.
BioPharmaceutical Strategy

Deals (04/2006)

Tracking Agouron

Despite growing sales of {Viracept}, Agouron's stock is in the doldrums. It needs a follow-on product, but doesn't have any great near-term prospects of its own and can't spend the research funds necessary to develop earlier ones without hurting earnings. Agouron is therefore turning to licensing later-stage drugs and simultaneously remaking its share structure with tracking stocks. Its idea is to sequester R&D spending into a separately traded cancer company and thereby spare the income statement of Agouron-Viracept.
BioPharmaceutical Business Strategies

Asian AIDS Markets: Growing Opportunities

With the world' s second largest concentration of HIV patients (after Africa), Southeast Asia is a booming market for AIDS products. Government initiatives to prevent and combat the spread of this virus present opportunities for Western companies in both diagnostic and therapeutic products.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Immune Response Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Immune Response BioPharma Inc.
  • Senior Management
  • Joseph F O'Neill, Pres. & CEO
  • Contact Info
  • Orchestra Therapeutics Inc.
    Phone: (760) 431-7080
    5935 Darwin Court
    Carlsbad, CA 92008-7399
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register